Compare Stocks: QTTB, CGEM, FBRX, and JBIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEM Cullinan Therapeutics	$17.73	$16.59	$5.68 ▼ $19.43	$1.14B	0.01	538,070 shs	361,734 shs
FBRX Forte Biosciences	$76.79	$37.32	$9.91 ▼ $77.20	$1.07B	2.6	2.17 million shs	1.16 million shs
JBIO Jade Biosciences	$21.96	$19.69	$6.67 ▼ $28.00	$1.08B	1.49	900,112 shs	463,136 shs
QTTB Q32 Bio	$15.60	$13.94	$1.57 ▼ $23.57	$264.58M	0.23	2.55 million shs	513,451 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEM Cullinan Therapeutics	0.00%	+7.45%	-2.21%	+20.37%	+142.88%
FBRX Forte Biosciences	0.00%	+0.25%	+74.84%	+195.35%	+654.32%
JBIO Jade Biosciences	0.00%	+11.19%	+4.82%	-11.67%	+193.19%
QTTB Q32 Bio	0.00%	-0.51%	+39.16%	+201.16%	+857.06%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEM Cullinan Therapeutics	$17.73	$16.59	$5.68 ▼ $19.43	$1.14B	0.01	538,070 shs	361,734 shs
FBRX Forte Biosciences	$76.79	$37.32	$9.91 ▼ $77.20	$1.07B	2.6	2.17 million shs	1.16 million shs
JBIO Jade Biosciences	$21.96	$19.69	$6.67 ▼ $28.00	$1.08B	1.49	900,112 shs	463,136 shs
QTTB Q32 Bio	$15.60	$13.94	$1.57 ▼ $23.57	$264.58M	0.23	2.55 million shs	513,451 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEM Cullinan Therapeutics	0.00%	+7.45%	-2.21%	+20.37%	+142.88%
FBRX Forte Biosciences	0.00%	+0.25%	+74.84%	+195.35%	+654.32%
JBIO Jade Biosciences	0.00%	+11.19%	+4.82%	-11.67%	+193.19%
QTTB Q32 Bio	0.00%	-0.51%	+39.16%	+201.16%	+857.06%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEM Cullinan Therapeutics	2.63	Moderate Buy	$32.14	81.29% Upside
FBRX Forte Biosciences	2.14	Hold	$72.50	-5.59% Downside
JBIO Jade Biosciences	2.90	Moderate Buy	$51.57	134.84% Upside
QTTB Q32 Bio	2.67	Moderate Buy	$30.00	92.31% Upside

Current Analyst Ratings Breakdown

Latest QTTB, CGEM, FBRX, and JBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	QTTB Q32 Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
7/29/2026	CGEM Cullinan Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$38.00 ➝ $39.00
7/28/2026	FBRX Forte Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	FBRX Forte Biosciences	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$74.00 ➝ $77.00
7/28/2026	QTTB Q32 Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$13.00 ➝ $36.00
7/27/2026	FBRX Forte Biosciences	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$77.00
7/27/2026	FBRX Forte Biosciences	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/27/2026	FBRX Forte Biosciences	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/27/2026	FBRX Forte Biosciences	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/21/2026	FBRX Forte Biosciences	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$74.00
7/21/2026	FBRX Forte Biosciences	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$74.00

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$6.92 per share	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$4.71 per share	N/A
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	$6.74 per share	N/A
QTTB Q32 Bio	$53.74M	4.92	$1.52 per share	10.29	$3.41 per share	4.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEM Cullinan Therapeutics	-$219.88M	-$3.10	N/A	N/A	N/A	N/A	-52.89%	-48.18%	N/A
FBRX Forte Biosciences	-$69.38M	-$4.64	N/A	N/A	N/A	N/A	-106.17%	-85.50%	8/13/2026 (Estimated)
JBIO Jade Biosciences	-$127.41M	-$2.02	N/A	N/A	N/A	N/A	-51.34%	-47.32%	N/A
QTTB Q32 Bio	$29.82M	$3.00	5.20	N/A	N/A	N/A	50.17%	29.49%	N/A

Latest QTTB, CGEM, FBRX, and JBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	FBRX Forte Biosciences	-$0.8785	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	CGEM Cullinan Therapeutics	-$0.7993	-$0.81	-$0.0107	-$0.81	$3.67 million	N/A
8/5/2026	Q2 2026	QTTB Q32 Bio	-$0.46	-$0.44	+$0.02	-$0.44	$0.75 million	N/A
5/11/2026	Q1 2026	FBRX Forte Biosciences	-$1.16	-$1.24	-$0.08	-$1.24	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	N/A
QTTB Q32 Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEM Cullinan Therapeutics	N/A	8.42	8.42
FBRX Forte Biosciences	N/A	2.75	2.75
JBIO Jade Biosciences	N/A	14.29	14.29
QTTB Q32 Bio	N/A	20.30	20.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEM Cullinan Therapeutics	86.31%
FBRX Forte Biosciences	77.63%
JBIO Jade Biosciences	N/A
QTTB Q32 Bio	31.32%

Insider Ownership

Company	Insider Ownership
CGEM Cullinan Therapeutics	8.60%
FBRX Forte Biosciences	4.40%
JBIO Jade Biosciences	23.06%
QTTB Q32 Bio	34.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEM Cullinan Therapeutics	30	64.36 million	58.82 million	Optionable
FBRX Forte Biosciences	5	13.89 million	13.28 million	Optionable
JBIO Jade Biosciences	20	49.36 million	37.98 million	N/A
QTTB Q32 Bio	39	16.96 million	11.11 million	N/A

QTTB, CGEM, FBRX, and JBIO Headlines

Recent News About These Companies

HC Wainwright Issues Positive Estimate for Q32 Bio Earnings

August 9 at 1:14 AM | americanbankingnews.com

HC Wainwright Forecasts Q32 Bio's Q3 Earnings (NASDAQ:QTTB)

August 7 at 6:11 AM | marketbeat.com

Q32 Bio tops estimates as alopecia drug advances toward late-stage trials

August 6, 2026 | seekingalpha.com

Q32 Bio Inc. (NASDAQ:QTTB) Receives Consensus Rating of "Moderate Buy" from Brokerages

August 6, 2026 | marketbeat.com

Q32 Bio (NASDAQ:QTTB) Issues Quarterly Earnings Results, Beats Estimates By $0.09 EPS

August 5, 2026 | marketbeat.com

Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 5, 2026 | prnewswire.com

Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 185.99%: Read This Before Placing a Bet

July 31, 2026 | zacks.com

HC Wainwright Raises Q32 Bio (NASDAQ:QTTB) Price Target to $36.00

July 30, 2026 | americanbankingnews.com

Q32 Bio (QTTB) Projected to Post Earnings on Wednesday

July 29, 2026 | marketbeat.com

Q32 Bio (NASDAQ:QTTB) Stock Price Expected to Rise, HC Wainwright Analyst Says

July 28, 2026 | marketbeat.com

Q32 Bio Inc. (NASDAQ:QTTB) Sees Large Increase in Short Interest

July 26, 2026 | marketbeat.com

Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice

July 20, 2026 | zacks.com

Q32 Bio: Bempikibart's Progress Keeps Me Bullish

July 17, 2026 | seekingalpha.com

Wall Street Analysts See an 80.12% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?

July 15, 2026 | zacks.com

Q32 Bio prices $200M equity raise

July 15, 2026 | msn.com

Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants

July 14, 2026 | prnewswire.com

Q32 Bio (NASDAQ: QTTB) - Share Price and Research

July 14, 2026 | intelligentinvestor.com.auI

Q32 Bio (QTTB) After Positive Trial Data Is It A Buy Or Already Fairly Valued

July 14, 2026 | finance.yahoo.com

Why Q32 Bio Stock Skyrocketed Today

July 13, 2026 | fool.com

Q32 Bio announces $200M offering of common stock and pre-funded warrants

July 13, 2026 | msn.com

Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

July 13, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTTB, CGEM, FBRX, and JBIO Company Descriptions

Cullinan Therapeutics NASDAQ:CGEM

$17.73 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$17.63 -0.10 (-0.59%)

As of 04:33 AM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Forte Biosciences NASDAQ:FBRX

$76.79 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$76.79 0.00 (0.00%)

As of 04:20 AM Eastern

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Jade Biosciences NASDAQ:JBIO

$21.96 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$22.10 +0.14 (+0.64%)

As of 04:06 AM Eastern

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Q32 Bio NASDAQ:QTTB

$15.60 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$15.75 +0.15 (+0.96%)

As of 06:37 AM Eastern

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QTTB, CGEM, FBRX, and JBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QTTB, CGEM, FBRX, and JBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QTTB, CGEM, FBRX, and JBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTTB, CGEM, FBRX, and JBIO Company Descriptions

Cullinan Therapeutics NASDAQ:CGEM

Forte Biosciences NASDAQ:FBRX

Jade Biosciences NASDAQ:JBIO

Q32 Bio NASDAQ:QTTB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QTTB, CGEM, FBRX, and JBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QTTB, CGEM, FBRX, and JBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QTTB, CGEM, FBRX, and JBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTTB, CGEM, FBRX, and JBIO Company Descriptions

Cullinan Therapeutics NASDAQ:CGEM

Forte Biosciences NASDAQ:FBRX

Jade Biosciences NASDAQ:JBIO

Q32 Bio NASDAQ:QTTB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools